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Abstract
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib
modulates the signaling of cytokines that are integral to lymphocyte activation, proliferation, and function. Thus,
tofacitinib therapy may result in suppression of multiple elements of the immune response. Serious infections have
been reported in tofacitinib RA trials. However, limited head-to-head comparator data were available within the
tofacitinib RA development program to directly compare rates of serious infections with tofacitinib relative to
biologic agents, and specifically adalimumab (employed as an active control agent in two randomized controlled
trials of tofacitinib).
Methods: A systematic literature search of data from interventional randomized controlled trials and long-term
extension studies with biologics in RA was carried out. Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) consensus was followed for reporting results of the review and meta-analysis. Incidence rates
(unique patients with events/100 patient-years) for each therapy were estimated based on data from randomized
controlled trials and long-term extension studies using a random-effects model. Relative and absolute risk comparisons
versus placebo used Mantel-Haenszel methods.
Results: The search produced 657 hits. In total, 66 randomized controlled trials and 22 long-term extension studies
met the selection criteria. Estimated incidence rates (95 % confidence intervals [CIs]) for abatacept, rituximab,
tocilizumab, and tumor necrosis factor inhibitors were 3.04 (2.49, 3.72), 3.72 (2.99, 4.62), 5.45 (4.26, 6.96), and
4.90 (4.41, 5.44), respectively. Incidence rates (95 % CIs) for tofacitinib 5 and 10 mg twice daily (BID) in phase 3 trials
were 3.02 (2.25, 4.05) and 3.00 (2.24, 4.02), respectively. Corresponding incidence rates in long-term extension studies
were 2.50 (2.05, 3.04) and 3.19 (2.74, 3.72). The risk ratios (95 % CIs) versus placebo for tofacitinib 5 and 10 mg BID were
2.21 (0.60, 8.14) and 2.02 (0.56, 7.28), respectively. Risk differences (95 % CIs) versus placebo for tofacitinib 5 and 10 mg
BID were 0.38 % (−0.24 %, 0.99 %) and 0.40 % (−0.22 %, 1.02 %), respectively.
Conclusions: In interventional studies, the risk of serious infections with tofacitinib is comparable to published rates for
biologic disease-modifying antirheumatic drugs in patients with moderate to severely active RA.
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Background
Many disease-modifying antirheumatic drugs (DMARDs),
particularly biologic agents, have become available with
the approval of the first tumor necrosis factor inhibitors
(TNFi). Despite documented efficacy in randomized
controlled trials, serious infections (e.g., those requiring
hospitalization and/or treatment with parenteral antibi-
otics) have been reported with varying degrees of risk and
remain a major concern in patients treated with DMARDs
[1]. Further, differences in trial designs pose challenges
when analyzing the safety of DMARDs.
Several meta-analyses have compared the incidence of
serious infections associated with various therapies for
rheumatoid arthritis [1–7]. Many included trials of bio-
logic DMARDs at dosages higher than those approved
by regulatory authorities, or did not account for differ-
ences in duration of exposure or differences arising from
pooling data from populations not restricted to moder-
ate to severely active rheumatoid arthritis. Recently,
Salgado et al. [2] included serious infection data for
tofacitinib.
Tofacitinib is an oral Janus kinase inhibitor for the
treatment of rheumatoid arthritis. Tofacitinib modulates
the signaling of cytokines that are integral to lymphocyte
activation, proliferation, and function [8, 9]. Thus,
tofacitinib therapy may result in suppression of multiple
elements of the immune response. The primary purpose
of this analysis was to summarize and contextualize the
risk of serious infections within the tofacitinib rheuma-
toid arthritis development program, based on a meta-
analysis of randomized controlled trials and long-term
extension studies of tofacitinib and biologic DMARDs.
Adalimumab (with or without methotrexate [MTX]) was
used as an active control agent in two randomized
controlled trials of tofacitinib [10, 11]. However, patient
numbers and exposure for adalimumab, and other
control agents (placebo, with or without nonbiologic
DMARDs), were limited due to trial design. Therefore, a
meta-analytic approach was considered useful to over-
come the inherent limitations of individual randomized
controlled trials in the evaluation of safety outcomes.
Methods
A systematic literature review identified safety data con-
cerning serious infections from published interventional
studies of biologic DMARDs and tofacitinib in patients
with rheumatoid arthritis. Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) con-
sensus was followed for results reporting [12].
Eligibility criteria
A search was conducted according to the Participants,
Interventions, Comparisons, Outcome, Study Design
(PICOS) statement, restricted to trials in moderate to
severely active rheumatoid arthritis [12]. Interventions in-
cluded tofacitinib and biologic agents currently licensed by
the US Food and Drug Administration and/or European
Medicines Agency for the treatment of rheumatoid arth-
ritis. Comparisons were versus placebo (in trials in patients
with inadequate response to DMARDs [DMARD-IR]) and
MTX (for trials in MTX-naive patients). The endpoint
of interest was serious infections (e.g., those requiring
hospitalization and/or parenteral antibiotics [outcome]).
Study designs included randomized controlled trials and
long-term extension studies.
Data were selected to match the population of tofa-
citinib trials: adults with moderate to severely active
rheumatoid arthritis. Trials were required to report data
for serious infections and have sufficient data to calcu-
late incidence rates (i.e., number of patients and patient-
years of exposure). Studies that combined two biologic
agents, duplicate reports, economic assessments, editorial
comments, and case reports, were excluded.
Information sources and search strategy
Articles published in English, in Medline, Embase, and
Biosis, up to October 2013 were selected. Regulatory sub-
missions within the US Food and Drug Administration
Summary Basis for Approvals, as well as European Public
Assessment Reports, were searched for serious infections
data for biologic DMARDs approved for moderate to
severely active rheumatoid arthritis.
Search criteria included keywords such as “rheumatoid
arthritis” and clinical trials of DMARDs (abatacept,
adalimumab, certolizumab, etanercept, golimumab, infli-
ximab, rituximab, and tocilizumab) (see section 1 in
Additional file 1). Citations within the assembled listing
were cross-referenced for completeness, and articles
were added based on the reverse search.
Study selection
The initial search was performed by an information
scientist with expertise in the field (C Hernandez). Inde-
pendent reviewers screened articles by title and abstract,
and any discrepancies were resolved by discussion
(M Boy, R Riese, S Krishnaswami, V Strand). Subse-
quently, a complete reading of articles was performed, and
articles that met the inclusion criteria were selected.
Tofacitinib data from five phase 2 randomized controlled
trials (NCT00147498, NCT00413660, NCT00550446,
NCT00603512, NCT00687193), six phase 3 randomized
controlled trials (NCT00960440, NCT00847613, NCT0
0814307, NCT00856544, NCT00853385, NCT01039688),
and two long-term extension studies (NCT00413699,
NCT00661661) were extracted for analysis. Tofacitinib
trials included patients who had failed nonbiologic
DMARDs or biologic DMARDs, including TNFi, where
the majority had failed MTX, and one trial in MTX-naive
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patients. For tofacitinib, only data from patients receiving
5 or 10 mg twice daily (BID) were included. Tofacitinib
long-term extension studies were ongoing at the time of
this analysis (August 2013 data cut); therefore, the data-
base had not been locked (i.e., some values may change
for the final, locked, study database). Publication details,
demographics, treatments, and serious infections were col-
lected. Trial quality was assessed using the Jadad scale [13].
Summary measures
Three summary measures were assessed. The first
estimated incidence rates (unique patients with events
per 100 patient-years’ exposure) for each agent, utilizing
a random-effects meta-analytic model [14] with a re-
stricted maximum likelihood estimator for between-
study variances. For tofacitinib, since there was access to
patient-level data, incidence rates were obtained from
pooling individual trials. For consistency, tofacitinib inci-
dence rates were also estimated using the same meta-
analysis model using summary incidence rates from each
trial. The second and third strategies estimated relative
risk (risk ratios) and risk differences for serious infec-
tions (with 95 % confidence intervals [CIs]), versus con-
trol, for each agent across randomized controlled trials
up to rescue of patients randomized to receive placebo.
Risk differences were expressed as differences in inci-
dence percentage with 95 % CIs. Analysis was performed
using the random-effects Mantel-Haenszel method [15].
Synthesis of results
Study effects were plotted against the inverse of their
standard errors to identify risk of publication bias, which
was assessed visually using funnel plots for symmetry,
and statistically, using the Egger test [16]. Heterogeneity
across trials was assessed using the I2 statistic [17].
An I2 value >40 % indicated moderate to substantial het-
erogeneity [18]. When heterogeneity was present, possible
causes were investigated via sensitivity analyses and meta-
regression, using factors such as trial quality (Jadad scale)
[13] and duration of exposure. p <0.05 was considered sig-
nificant, except in the meta-regression analysis, where the
significance level was 0.1. Additional sensitivity analyses,
regardless of heterogeneity, excluded studies with zero
incidence rates, long-term extension studies, studies with
incidence rates reported on multiple occasions after dif-
ferent durations of exposure, and studies that included
doses not approved for use by the US Food and Drug
Administration or European Medicines Agency.
To explore additional clinical questions pertinent to
use of these therapies in rheumatoid arthritis, namely as
monotherapy or in MTX-naive patients, separate ana-
lyses were conducted for trials of monotherapy in
DMARD-IR patients, in which DMARDs were discon-
tinued prior to treatment initiation, and randomized
controlled trials in MTX-naive patients. Incidence rates
were calculated using the R (version 2.12.2) metafor
package [19]. Risk ratios and risk differences were calcu-
lated using Review Manager Software (RevMan) version
5.2 [20]. However, as RevMan did not incorporate trials
with zero incidence in both arms, a sensitivity analysis
was performed using R.
Results
Trials included in the meta-analysis
Figure 1 illustrates the article selection process. The
search identified 657 articles, of which 66 were random-
ized controlled trials and 22 were long-term extension
studies, representing 40,512 patients. Data were extracted
for analysis of serious infections as shown in Fig. 1, includ-
ing 57, 11, 8, and 13 trials for TNFi, abatacept, rituximab,
and tocilizumab, respectively. Tofacitinib results from
phase 3 randomized controlled trials only, long-term ex-
tension studies only, and integrated data from pooled
phase 2, phase 3, and long-term extension studies were
included in the contextualization analysis. Individual trial
characteristics for the 98 articles used in the analysis, in-
cluding the 88 studies, are presented in section 2, Table 1
in Additional file 1.
A summary of age, gender, and trial duration by drug
is presented in section 4 in Additional file 1. For relative
risk and risk difference analyses there were 48 trials in
DMARD-IR patients and 14 in MTX-naive patients. All
trials included patients with moderate to severely active
rheumatoid arthritis, with demographics and baseline
characteristics comparable to those in the tofacitinib
clinical development program. Median trial duration was
longer for abatacept than for tofacitinib.
Contextualization of serious infection rates for biologic
DMARDs and tofacitinib
Estimates of incidence rates (95 % CIs) for serious infec-
tions were: 3.04 (2.49, 3.72) for abatacept (I2 = 39.21 %,
p = 0.083) with evidence of publication bias in the funnel
plot (Egger test, p = 0.013); 3.72 (2.99, 4.62) for ritu-
ximab (I2 = 0 %, p = 0.68) without evidence of pub-
lication bias (p = 0.858); 5.45 (4.26, 6.96) for tocilizumab
(I2 = 61.62 %, p = 0.0003) without evidence of publication
bias (p = 0.178); and 4.90 (4.41, 5.44) across TNFi ther-
apies (I2 = 64.56 %, p <0.0001) without evidence of publi-
cation bias (p = 0.113) (Fig. 2). Treatment duration and
long-term, open-label studies were identified as causes
of heterogeneity. For funnel plots, see section 6 in
Additional file 1.
Exclusion of studies with Jadad score <3 (typically
long-term, open-label studies), and including duration of
exposure as a covariate, reduced I2 values significantly
for therapies with high heterogeneity, including ada-
limumab (I2 = 25.3 %, p = 0.18), etanercept (I2 = 0 %,
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Fig. 1 Flow diagram of the literature selection process. DMARD(−IR) disease-modifying antirheumatic drug(−inadequate responder),
LTE long-term extension
Fig. 2 Incidence rates for serious infections with biologic DMARDs and tofacitinib across RCTs* and LTE studies. The results displayed did not
include the continuity factor to account for zero incidence rates due to the low percentage of zero incidence rates for serious infections within
these trials (<10 %). Tofacitinib data as of April 2013. *Clinical trial data published between 1999 and 2013. BID twice daily, CI confidence interval,
DMARD disease-modifying antirheumatic drug, LTE long-term extension, pt-yrs patient-years, RCT randomized controlled trial, TNFi tumor necrosis
factor inhibitors
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p = 0.151), and tocilizumab (I2 = 8.7 %, p = 0.085).
Regardless of the analyses, incidence rate point
estimates differed by <1 event/100 patient-years
(adalimumab 5.04 vs. 4.29, etanercept 4.06 vs. 4.26,
and tocilizumab 5.45 vs. 4.99).
Incidence rates (95 % CIs) for tofacitinib 5 and 10 mg
BID in phase 3 randomized controlled trials were 3.02
(2.25, 4.05) and 3.00 (2.24, 4.02), respectively. Corre-
sponding incidence rates in long-term extension studies
were 2.50 (2.05, 3.04) and 3.19 (2.74, 3.72) (Fig. 2). The
meta-analytic incidence rates (95 % CIs) for tofacitinib 5
and 10 mg BID were 2.83 (1.57, 5.08), and 2.31 (1.21,
4.41), respectively. There was no evidence of heterogen-
eity for tofacitinib 5 mg BID (I2 = 20.5 %, p = 0.532) or
tofacitinib 10 mg BID (I2 = 24.1 %, p = 0.46), and no evi-
dence of publication bias (Egger test p values: 0.288 and
0.354 for tofacitinib 5 and 10 mg, respectively). Sen-
sitivity analyses were generally consistent with the pri-
mary analysis (see section 5 in Additional file 1).
Risk ratio and risk difference for serious infection in
patients with inadequate response to DMARDs
Comparative analyses of DMARD-IR trials (n = 48) are
shown in Fig. 3 (relative risk) and Fig. 4 (risk difference).
Studies were predominantly on background MTX.
Relative risk values comparing DMARDs with placebo
ranged from 0.83 to 2.27. There was only one random-
ized controlled trial with etanercept (DMARD-IR trials
were generally not conducted in the late 1990s and early
2000s) [21], with a risk ratio (95 % CI) of 1.0 (0.07,
15.24) (Fig. 3). The risk ratio for TNFi versus placebo in
DMARD-IR trials was 1.5 (1.00, 2.25). The risk ratio for
tofacitinib versus placebo in phase 3 trials was 2.21
(0.60, 8.14) for 5 mg BID and 2.02 (0.56, 7.28) for 10 mg
BID. There was no evidence of publication bias (Egger
test p values: 0.17–0.94 across therapies).
Risk differences (95 % CI) versus placebo were 0.94 %
(0.25 %, 1.63 %) for TNFi therapies, 0.4 % (−0.72 %,
1.51 %) for abatacept, 1.51 % (0.68 %, 2.33 %) for toci-
lizumab, −0.42 % (−1.63 %, 0.79 %) for rituximab, 0.38 %
(−0.24 %, 0.99 %) for tofacitinib 5 mg BID, and 0.40 %
(−0.22 %, 1.02 %) for tofacitinib 10 mg BID (Fig. 4). With
the exception of adalimumab (p = 0.04) there was no evi-
dence of publication bias (Egger test p values: 0.27–0.86
across other therapies).
In relative risk and risk differences analyses, I2 values
were <40 % in all cases with one exception: the I2 value
for the adalimumab risk difference analysis was 49 %,
which reduced to 15 % following exclusion of a study
with the highest exposure duration (approximately
9 months).
Serious infection risk in monotherapy and
methotrexate-naive populations
Our database included five randomized controlled trials of
TNFi monotherapy in DMARD-IR patients and 14 ran-
domized controlled trials of biologic DMARDs in MTX-
naive patients. Among monotherapy trials, the incidence
rate (95 % CI) estimate was 5.34 (1.75, 16.3) events/100
patient-years (I2 = 39.92, p = 0.23) with borderline evi-
dence of publication bias (p = 0.074) (see Figure S9 in
Additional file 1). Within the MTX-naive population, risk
ratio (95 % CI) point estimates versus MTX were 0.46–2.8
across biologic DMARDs, 1.24 (0.87, 1.77) for TNFi, 1.10
(0.39, 3.11) for tofacitinib 5 mg BID monotherapy, and
0.75 (0.25, 2.26) for tofacitinib 10 mg BID monotherapy
(see sections 3 and 5.2.2 in Additional file 1). Risk dif-
ference point estimates versus MTX ranged from −2.78 %
Fig. 3 Risk ratios for biologic DMARDs and tofacitinib versus placebo across RCTs in DMARD-IR patients. Studies were predominantly on background
methotrexate. BID twice daily, CI confidence interval, DMARD(−IR) disease-modifying antirheumatic drug(−inadequate responder), RCT randomized
controlled trial, TNFi tumor necrosis factor inhibitors
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to 3.70 % across biologic DMARDs, 0.65 % (−0.33 %,
1.63 %) for TNFi, 0.26 % (−2.63 %, 3.15 %) for tofaciti-
nib 5 mg BID monotherapy, and −0.67 % (−3.38,
2.03) for tofacitinib 10 mg BID (Fig. 5, and sections 3
and 5.3.2 in Additional file 1).
Discussion
These analyses, which included data from 66 random-
ized controlled trials and 22 long-term extension studies,
provide a substantial integrated assessment of serious
infection risk in patients with moderate to severely
Fig. 4 Risk differences for biologic DMARDs and tofacitinib versus placebo across RCTs in DMARD-IR patients. Studies were predominantly on
background methotrexate. BID twice daily, CI confidence interval, DMARD(−IR) disease-modifying antirheumatic drug(−inadequate responder),
RCT randomized controlled trial, TNFi tumor necrosis factor inhibitors
a
b
Fig. 5 Risk ratios (a) and risk differences (b) for serious infections across RCTs in methotrexate-naive patients. Tofacitinib data are from the phase
3 ORAL Start study. BID twice daily, CI confidence interval, RCT randomized controlled trial, TNFi tumor necrosis factor inhibitors
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active rheumatoid arthritis, and evaluate results from the
tofacitinib clinical development program in the context
of TNFi and other biologic DMARDs. As identified in a
commentary on a recent meta-analysis of serious infec-
tions data 106 trials of biologic DMARDs in rheumatoid
arthritis [7], selection of an appropriate treatment for a
given patient is informed by how infection incidence
vary according to drug, and individual patient character-
istics [22]. Thus, an advantage of the analytical approach
used here is that estimates of serious infection risk were
obtained for individual DMARDs, with a further break-
down of risk according to prior treatment (MTX-naive
versus DMARD inadequate responders). Despite limita-
tions inherent in the design of randomized controlled
trials (including small sample sizes, limited trial dura-
tions, and unequal exposure between active and control
[placebo] therapies for ethical reasons), the typical onset
of serious infections observed (within the first 3–12
months of treatment) and inclusion of data from long-
term extension studies provide a holistic view of serious
infection risk in randomized controlled trials.
We attempted to estimate incidence rates as precisely
as possible, using all available data for each therapy, and
provided comparative (relative risk) and absolute (risk
difference) assessments versus controls, using data from
randomized controlled trials only. Collectively, the inci-
dence rates, risk ratio, and risk difference estimates for
approved doses of biologic DMARDs do not indicate
any significant differences in the risk of serious infec-
tions with tofacitinib compared with TNFi and biologic
DMARDs in DMARD-IR patients. Numerical differences
were noted, e.g., between tofacitinib and tocilizumab,
when incidence rates were compared, but risk ratio and
risk difference estimates indicated similar risk. CIs for risk
differences appeared more precise compared with risk
ratios, likely due to the limited number of events in the
placebo groups over 3 months’ exposure (one event across
all tofacitinib randomized controlled trials).
The present study explored two additional clinical
questions pertinent to the clinical use of these therapies
in rheumatoid arthritis, namely as monotherapy or com-
pared with MTX in MTX-naive patients. The incidence
rate (95 % CI) for serious infection across TNFi (5.34
[1.75, 16.3]) was consistent with the incidence rate from
DMARD-IR studies (4.9 [4.4, 5.4]). In two tofacitinib
monotherapy trials of 6 months’ duration (in DMARD-
IR patients) [10, 23], no serious infections were reported
with tofacitinib 5 mg BID (n = 292) or placebo (n = 181,
3-month period) and one event with tofacitinib 10 mg
BID (n = 306). Additional data are needed to ascertain
whether tofacitinib is associated with a lower risk of
serious infections when administered as monotherapy ver-
sus combination therapy (with MTX). In contrast, studies
in MTX-naive patients provide a robust comparison to
MTX as they allow comparison to active control over the
full study duration. While CIs from the relative risk and
risk difference analyses in this population include the null,
point estimates indicate a similar magnitude of risk of
serious infections with biologic DMARDs in MTX-naive
patients (see section 3 in Additional file 1). An analysis of
tofacitinib in biologic DMARD-naive patients versus
biologic DMARD-IR patients with rheumatoid arthritis,
conducted separately and not as part of this meta-analytic
framework, showed that the incidence rates for events of
special interest, including serious infections, appear con-
sistent between the two populations [24].
Two tofacitinib studies provide important direct evi-
dence to assess the risk of serious infections [11, 25].
ORAL Start, a 2-year study comparing tofacitinib with
MTX in MTX-naive patients [25], showed a similar inci-
dence of serious infections with tofacitinib 5 mg BID
(11/373 [incidence rate (95 % CI) 1.82 (1.01, 3.28)]) and
tofacitinib 10 mg BID (8/397 [incidence rate (95 % CI)
1.23 (0.62, 2.46)]) compared with MTX (5/186 [inci-
dence rate (95 % CI) 1.87 (0.78, 4.49)]). ORAL Standard
[11] demonstrated a higher incidence of serious infec-
tions with tofacitinib 5 (7/204 [3.4 %]) and 10 mg BID
(8/201 [4.0 %]) (both plus MTX) versus adalimumab
plus MTX (3/204 [1.5 %]). However, the incidence rate
(95 % CI) for serious adverse events with adalimumab
plus MTX from this 1-year trial (1.68/100 patient-years
[0.54, 5.02]) was in the lower end of the range of pub-
lished adalimumab studies (range: 0.7 to 37 events/100
patient-years) and lower than the incidence rate estimate
from this entire analysis (5.04 events/100 patient-years
[3.8, 6.69]). Patient demographics and disease character-
istics in the ORAL Standard study may not explain this
as they do not present unique differences relative to
other reported adalimumab studies.
Limitations of this analysis include the reliance upon
published data describing the use of biologic agents in
patients with rheumatoid arthritis. While publication
bias typically results in an attenuation of effect estimates
for safety endpoints, resultant bias is not measureable.
Second, study-specific covariates (i.e., baseline comor-
bidities, stage and duration of disease, variations by geo-
graphic region and publication year) were not evaluated.
Consequently, the incidence rate data presented may not
be directly applicable to all patient subgroups with
rheumatoid arthritis. Additionally, the trials represent a
range with respect to patient-years of exposure and length
of controlled treatment (longer- versus shorter-term). If
the risk of serious infection varies over time, then inclu-
sion of shorter-term trials could have biased results. A
weak relationship between incidence rates and study
duration can be noted, with higher incidence rates for
shorter study durations. This could be related to the
phenomenon of “depletion of susceptibles, survival bias,
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or higher disease activity at baseline” [26, 27]. Finally,
patient dropout must be considered as a possible influence
on the results [28]. For trials that reported incidence rates,
it is reasonable to expect that individual patient dropout
information would be factored into the exposure duration.
However, for trials that did not directly report incidence
rates, nominal exposure time was used to impute the inci-
dence rate. This method has the potential to underesti-
mate the true incidence rate as well as the variance
estimate because it assumes no dropouts. For tofacitinib,
the availability of patient-level data allowed incidence rates
to be calculated based on individual exposure information.
The pooled and meta-analytic incidence rates were
comparable.
A network meta-analysis was not pursued because
of differences in randomized controlled trials con-
ducted in RA with respect to patient populations and
comparator therapy, e.g., MTX in MTX-naïve patients,
placebo + background DMARD therapy in DMARD-IR
patients, and placebo in monotherapy trials. Such an ana-
lysis would have required an assumption to be made that
the control arms in these settings are the same in order to
have a node that could serve to compare incidence rates
between therapies. This was an assumption was not
supported by the evidence in the literature collected
over the past decade and would have increased the
potential for combining studies that were not appro-
priately similar to allow quantitative comparisons between
biologic DMARDs and tofacitinib to be generated. This
was also the reason why MTX-naïve and DMARD-IR
comparisons were performed separately, more so since the
duration of placebo treatment in DMARD-IR studies is
generally much shorter (3–6 months) than the duration of
MTX treatment in MTX-naïve patients (1–2 years), and
this analysis shows differences in the incidence of infec-
tions between the different populations. While a network
meta-analysis could be performed for each population sep-
arately, it was considered unlikely to provide additional
value beyond the pairwise approach used in this analysis to
qualitatively compare the therapies.
The results of the present analysis corroborate findings
from other recent analyses [1, 3, 4]. Leombruno et al. re-
ported an odds ratio (95 % CI) of 1.21 (0.89, 1.63) for
serious infection with TNFi administered at recom-
mended doses [4]. Thompson and colleagues evaluated
studies among DMARD-naive patients with early rheu-
matoid arthritis, treated with TNFi, and found the odds
ratio for serious infection (TNFi versus MTX control)
was not statistically more frequent (1.28 [0.82, 2.00]) [3].
Michaud et al. also reported a higher risk of serious
infection with adalimumab, certolizumab pegol, and
infliximab, which appears to contribute to higher rates
of discontinuations [1]. Within our analysis, the risk
ratio (95 % CI) for TNFi was 1.45 (0.98, 2.17) and 1.25
(0.86, 1.81) in the DMARD-IR and MTX-naive popu-
lations, respectively. Similarly, Salgado et al. reported
that the risk ratio (95 % CI) for serious infections
was not significantly elevated in patients receiving
protein kinase inhibitors compared with controls
(fostamatinib: 1.07 [0.40, 2.91]; Janus kinase inhibi-
tors: 1.68 [0.71, 3.91]) [2]. In this study, the reported
risk ratio (95 % CI) for serious infection in patients
exposed to tofacitinib in randomized controlled trials
(across multiple indications) was 1.57 (0.65, 3.82), in
line with the present analysis.
Concomitant corticosteroid intake has a definitive role
in the risk of serious infections. However, the detailed
information necessary to allow such analysis in a meta-
analysis framework was not reported in most of the
articles – thus precluding inclusion in this analysis.
Concomitant corticosteroid intake was investigated for
tofacitinib as part of a multivariate Cox proportional
hazards analysis of risk factors. The results confirm that,
as with biologic DMARDs, concomitant corticosteroid
intake results in increase in the risk of serious infections
[29]. Further, a thorough evaluation of serious infection
risk should be contextualized within treatment benefits.
Conclusions
The results of this meta-analysis indicate that in interven-
tional studies, the rates of serious infections associated
with tofacitinib in patients with moderate to severely
active rheumatoid arthritis are within the range of those
reported for biologic DMARDs.
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